NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Codagenix

Codagenix

Private
Farmingdale, New YorkHealthcare & Life Scienceshttps://codagenix.com/

Last Round

Grant

Oct 24, 2023

Total Funding Raised

$65.18M

Company Overview

Codagenix is a biotechnology company that develops live-attenuated viral vaccines and therapeutics using a synthetic biology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Application

Keywords

synthetic biologylive-attenuated vaccineintranasal vaccinevaccine designcodon deoptimizationbiotech platformmucosal immunitypandemic preparednessclinical-stage biotechBARDAvaccine developmentnext-gen vaccinesai-driven drug discoverynasal spray vaccineplatform technology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Codagenix Comparables

Compare Codagenix with similar companies based on industry and business-model similarity.

Codagenix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CyanVac LLC
91%
Blue Lake Biotechnology, Inc.
88%
Vivaldi Biosciences, Inc.
83%

Codagenix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 24, 2023
Series B ExtensionFeb 15, 2023
GrantAug 17, 2022
GrantJul 22, 2020
Series BJan 14, 2020
VC Round
Oct 12, 2017

Key People

Founding team and executive leadership

Steffen Mueller

Founder, President, Chief Scientific Officer

Founding Team

Qi Ana McKnight

Co-Chief Executive Officer

Executive Team

Tyler Cook

Chief Financial Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 24, 2023

    Received $6M from U.S. Department of Health and Human Services.

  • Feb 15, 2023

    $25M round led by Euclidean Capital and Serum Institute of India.

Codagenix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Codagenix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Codagenix's valuation, stock price, and market status.

Firmographic Details

HeadquartersFarmingdale, New York
Employee Range19
Year Founded2011
Last FundingOct 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.